ArticleInternational journal of nanomedicine2013
A nonviral pHEMA+chitosan nanosphere-mediated high-efficiency gene delivery system.
Article in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Biopolymer-based Carriers for DNA Vaccine Design.Angewandte Chemie (International ed. in English) · 2021Review
- Article
- Design of PEI-conjugated bio-reducible polymer for efficient gene delivery.International journal of pharmaceutics · 2018Article
- Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus.Bioengineering (Basel, Switzerland) · 2018Article
- Potential applications and human biosafety of nanomaterials used in nanomedicine.Journal of applied toxicology : JAT · 2018Review
- Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus.Vaccines · 2016Review
- Gold nanorods inhibit respiratory syncytial virus by stimulating the innate immune response.Nanomedicine : nanotechnology, biology, and medicine · 2016Article
- Immunogenicity of RSV F DNA Vaccine in BALB/c Mice.Advances in virology · 2016Article
- Novel pegylated silver coated carbon nanotubes kill Salmonella but they are non-toxic to eukaryotic cells.Journal of nanobiotechnology · 2015Article
- Transactivator of transcription (TAT) peptide- chitosan functionalized multiwalled carbon nanotubes as a potential drug delivery vehicle for cancer therapy.International journal of nanomedicine · 2015Article
- Cross-linked polyethylenimine-tripolyphosphate nanoparticles for gene delivery.International journal of nanomedicine · 2014Article
- DNA-encapsulated magnesium phosphate nanoparticles elicit both humoral and cellular immune responses in mice.Results in immunology · 2014Article
- Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.Advances in virology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The transport of DNA into eukaryotic cells is minimal because of the cell membrane barrier, and this limits the application of DNA vaccines, gene silencing, and gene therapy. Several available transfection reagents and techniques have been used to circumvent this problem. Alternatively, nonviral nanoscale vectors have been shown to bypass the eukaryotic cell membrane. In the present work, we developed a unique nanomaterial, pHEMA+chitosan nanospheres (PCNSs), which consisted of poly(2-hydroxyethyl methacrylate) nanospheres surrounded by a chitosan cationic shell, and we used this for encapsulation of a respiratory syncytial virus (RSV)-F gene construct (a model for a DNA vaccine). The new nanomaterial was capable of transfecting various eukaryotic cell lines without the use of a commercial transfection reagent. Using transmission electron microscopy, (TEM), fluorescence activated cell sorting (FACS), and immunofluorescence, we clearly demonstrated that the positively charged PCNSs were able to bind to the negatively charged cell membrane and were taken up by endocytosis, in Cos-7 cells. Using quantitative polymerase chain reaction (qPCR), we also evaluated the efficiency of transfection achieved with PCNSs and without the use of a liposomal-based transfection mediator, in Cos-7, HEp-2, and Vero cells. To assess the transfection efficiency of the PCNSs in vivo, these novel nanomaterials containing RSV-F gene were injected intramuscularly into BALB/c mice, resulting in high copy number of the transgene. In this study, we report, for the first time, the application of the PCNSs as a nanovehicle for gene delivery in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.